IRC15 Antibody

What is LRRC15 and what cellular functions does it regulate?

LRRC15 (Leucine-rich repeat-containing protein 15, also known as LIB or hLib) is a protein implicated in various cellular processes. It functions as a leucine-rich repeat protein that was initially identified in relation to beta-amyloid protein . LRRC15 has emerged as a significant protein in cellular biology, particularly in the context of microbial infections. The protein has been shown to modulate the ability of SARS-CoV-2 to infect host cells through direct interaction with the viral spike protein . Importantly, LRRC15 does not function as a SARS-CoV-2 entry receptor but instead sequesters virions and antagonizes SARS-CoV-2 infection of ACE2-positive cells when expressed on nearby cells, suggesting a protective mechanism against viral infection .

What detection methods are validated for LRRC15 antibodies?

The LRRC15 antibody [EPR8188(2)] is a rabbit recombinant monoclonal antibody that has been specifically validated for immunofluorescence (ICC/IF) and western blot (WB) applications . This antibody has demonstrated reactivity with human, mouse, and rat samples, making it versatile for cross-species research . When using this antibody for western blot applications, a dilution of 1/1000 has been validated as effective . Unlike some antibodies that require validation in western blot before application in other methods, the LRRC15 antibody has been directly validated for immunofluorescence, allowing researchers to confidently employ it in this application without preliminary western blot validation .

How should researchers evaluate the specificity of LRRC15 antibodies?

When evaluating LRRC15 antibody specificity, researchers should implement a comprehensive validation strategy that includes:

• Comparative analysis between expressing and non-expressing cells/tissues for the target protein

• Verification of correct cellular localization patterns in relevant tissues

• Confirmation of correct band size in western blot applications

• Implementation of proper controls including isotype controls

• Cross-reactivity testing with related proteins, especially for antibodies without known epitope mapping

It's important to note that demonstrating stain distribution on a single cell line with a peak away from background is insufficient evidence of specificity . Proper validation requires comparative approaches and multiple methodological confirmations.

How can LRRC15 antibodies be optimized for studying SARS-CoV-2 infection mechanisms?

When studying LRRC15's role in SARS-CoV-2 infection using antibodies, researchers should implement a multi-faceted experimental design:

• Co-immunoprecipitation experiments to directly capture LRRC15-spike protein interactions

• Immunofluorescence studies to visualize the co-localization of LRRC15 with viral particles

• Cell-based assays comparing infection rates between LRRC15-expressing and non-expressing cells

• Proximity ligation assays to confirm direct protein-protein interactions in situ

The research indicates that LRRC15 sequesters SARS-CoV-2 virions and antagonizes infection of ACE2-positive cells when expressed on nearby cells . This "in trans" protective mechanism requires careful experimental design to distinguish from direct receptor-mediated effects. When conducting these studies, researchers should include appropriate controls for antibody specificity, including LRRC15 knockdown cells alongside wild-type cells to confirm signal specificity .

What considerations are critical when using LRRC15 antibodies in complex tissue microenvironments?

When applying LRRC15 antibodies to complex tissue microenvironments:

• Tissue-specific validation is essential as antibody performance can vary between tissues

• For immunohistochemistry applications, researchers must validate cellular localization patterns in relevant tissues rather than relying solely on cancerous tissue staining

• Comparison between multiple LRRC15 antibodies targeting different epitopes will strengthen confidence in observed staining patterns

• Background autofluorescence must be carefully controlled, particularly in tissues with high connective tissue content where LRRC15 may be expressed

Researchers should specifically address whether observed signals correspond to expected cellular compartmentalization of LRRC15. The antibody validation hierarchy for tissue applications ranges from "unclear cellular location staining on cancerous tissue only" (lowest confidence) to "relevant tissues with clear and correct cellular location staining" (highest confidence) .

What are the recommended validation protocols for confirming LRRC15 antibody specificity?

A comprehensive validation protocol for LRRC15 antibodies should include:

For western blot applications, testing on relevant cell types showing the correct band size (approximately 70-90 kDa for LRRC15) with appropriate controls represents the gold standard for validation . For immunoprecipitation studies, comparing with isotype controls and detecting with a different antibody provides the strongest evidence of specificity . Regardless of the technique, researchers should always include both positive and negative controls in their experimental design.

How should researchers address batch-to-batch variability in LRRC15 antibody experiments?

Batch-to-batch variability is a critical consideration for maintaining experimental reproducibility. Researchers should:

• Maintain detailed records of antibody lot numbers for each experiment

• Perform validation tests with each new antibody batch

• Consider creating a reference standard by preserving aliquots of well-validated batches

• Use defined formulations rather than undefined ones, as the latter significantly affect reproducibility

Antibodies with defined epitopes or those raised against immunizing peptides are inherently more robust compared to antibodies raised against entire proteins, as the limited size of the antigen increases the chance of reproducible characteristics . For monoclonal antibodies like the LRRC15 antibody [EPR8188(2)], recombinant production helps ensure consistency, but validation remains essential with each new lot .

What are the common pitfalls in western blot applications of LRRC15 antibodies and how can they be resolved?

Common western blot issues with LRRC15 antibodies include:

• Non-specific bands: Increase blocking stringency (5% BSA instead of milk) and optimize antibody dilution (1:1000 recommended for LRRC15 antibody [EPR8188(2)])

• Weak signal: Increase exposure time, protein loading, or consider using enhanced chemiluminescence reagents

• High background: Increase washing duration and frequency, reduce primary antibody concentration

• Unexpected band size: Verify sample preparation conditions, as proteolytic degradation or post-translational modifications may affect migration pattern

When troubleshooting, researchers should systematically alter one parameter at a time while keeping others constant. For LRRC15 detection, inclusion of positive control samples (cells known to express LRRC15) alongside experimental samples is crucial for interpreting results accurately .

How can researchers distinguish between specific and non-specific immunofluorescence signals when using LRRC15 antibodies?

To distinguish specific from non-specific immunofluorescence signals:

• Include proper negative controls (secondary antibody only, isotype control)

• Perform peptide competition assays where available

• Compare staining patterns with LRRC15 knockdown or knockout samples

• Verify subcellular localization corresponds with known LRRC15 distribution

• Use orthogonal detection methods to confirm expression in tissues of interest

A single-cell line showing a staining distribution with a peak away from background is insufficient evidence of specificity . Instead, researchers should compare expressing and non-expressing cells under identical conditions. For LRRC15, which has roles in SARS-CoV-2 interaction, co-localization studies with viral proteins can provide functional validation of antibody specificity in relevant experimental contexts .

How does LRRC15 interact with SARS-CoV-2 spike protein and what methodologies best capture this interaction?

LRRC15 has been shown to modulate SARS-CoV-2 infection through direct interaction with the viral spike protein . This interaction does not facilitate viral entry but instead appears to sequester virions and antagonize infection of ACE2-positive cells when LRRC15 is expressed on nearby cells . To study this interaction:

• Co-immunoprecipitation: Using LRRC15 antibodies to pull down protein complexes, followed by detection of spike protein

• Proximity ligation assays: To visualize protein interactions in fixed cells

• FRET/BRET assays: For real-time monitoring of protein-protein interactions

• Surface plasmon resonance: To determine binding kinetics between purified proteins

When designing experiments to study this interaction, researchers should consider using cell lines with differential expression of LRRC15 and ACE2 to distinguish the "in trans" protective mechanism from direct receptor interactions .

What experimental designs can effectively measure LRRC15's ability to antagonize SARS-CoV-2 infection in trans?

To study LRRC15's trans-antagonism of SARS-CoV-2 infection, researchers can implement the following experimental designs:

• Co-culture systems: Mixing LRRC15-expressing cells with ACE2-positive target cells and measuring infection rates

• Conditioned media experiments: Testing if soluble factors from LRRC15-expressing cells affect infection

• Transwell assays: Separating LRRC15-expressing cells from target cells by a permeable membrane

• Cell-specific knockdown: Using siRNA or CRISPR to selectively modulate LRRC15 expression

For each design, quantification of infection rates through viral RNA, protein expression, or reporter systems provides measurement of antagonistic effects. The LRRC15 antibody can be used in these systems to confirm protein expression and potentially block function through neutralization . When interpreting results, researchers should consider that LRRC15 "sequesters virions" rather than acting as an entry receptor, suggesting a mechanism distinct from competitive inhibition of ACE2 binding .

What quality control measures should researchers implement when using LRRC15 antibodies across different experimental platforms?

To ensure reproducibility when using LRRC15 antibodies across different experimental platforms:

• Validate the antibody specifically for each application (WB, IF, IHC) rather than assuming cross-application validity

• Document detailed protocols including antibody concentrations, incubation times, and buffer compositions

• Maintain consistent experimental conditions including cell passage numbers and tissue processing methods

• Include appropriate positive and negative controls for each experiment

• Consider antibody storage conditions and avoid repeated freeze-thaw cycles which can affect integrity

Researchers should recognize that validation in one application does not automatically translate to another application. The notion that every antibody needs validation in western blot before moving to other assays is flawed and risks losing valuable antibodies that may work in immunofluorescence but not in western blot . For LRRC15 antibody [EPR8188(2)], separate validation for western blot and immunofluorescence applications has been performed .

How can researchers effectively document and report LRRC15 antibody validation to ensure research reproducibility?

Effective documentation and reporting of LRRC15 antibody validation should include:

• Complete antibody information (supplier, catalog number, lot number, clone for monoclonals)

• Detailed validation methods performed specifically for the experimental system

• Images of positive and negative controls demonstrating specificity

• Description of optimization steps undertaken for the specific application

• Any limitations or cross-reactivity observed during validation

When publishing results, researchers should provide this information in methods sections or supplementary materials to allow others to reproduce the work. For LRRC15 research specifically, documenting whether the antibody effectively recognizes the native conformation relevant to SARS-CoV-2 binding is crucial for studies investigating this interaction . Researchers should also specify which epitope their antibody recognizes, as this may affect interpretation of functional studies, particularly those involving protein-protein interactions.